Indeed, many studies have proved the prevalence of PD-L1 expression in both breast cancer cell lines and clinical samples of breast cancer, mainly in TNBC patients [48–50], indicating that the aggressive subset of patients may benefit from PD1/PDL1 blockade. Here, CD274 is linked to breast carcinoma.